For a hemodialysis patient weighing 85 kg, what teicoplanin dosing regimen will achieve a trough concentration of 20–40 mg/L?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Teicoplanin Dosing for Hemodialysis Patient (85 kg) Targeting Trough 20-40 mg/L

For an 85 kg hemodialysis patient targeting a trough of 20-40 mg/L, administer 1020 mg (12 mg/kg) as a loading dose, followed by 510 mg (6 mg/kg) on days 2 and 3, then 510 mg once weekly after each dialysis session.

Dosing Algorithm

Loading Phase (Days 1-3):

  • Day 1: 1020 mg (12 mg/kg × 85 kg) as loading dose
  • Day 2: 510 mg (6 mg/kg × 85 kg)
  • Day 3: 510 mg (6 mg/kg × 85 kg)

Maintenance Phase (Day 4 onwards):

  • 510 mg once weekly after dialysis session

Rationale

The guideline-recommended hemodialysis regimen uses 12 mg/kg for the loading dose specifically because you're targeting the higher trough range of 20-40 mg/L 1. The standard 6 mg/kg loading dose is insufficient for achieving troughs >20 mg/L, which are required for serious infections like S. aureus endocarditis or septic arthritis 1.

The Belgian guidelines explicitly state that the 12 mg/kg dosing (rather than 6 mg/kg) should be used "in case of S. aureus endocarditis or septic arthritis" where trough concentrations of at least 20 mg/L are needed 1. Your target of 20-40 mg/L falls into this higher therapeutic range.

Critical Considerations

Timing with Dialysis:

  • Administer doses after dialysis sessions to minimize drug removal
  • Teicoplanin is minimally dialyzable but timing optimization prevents unnecessary losses

Therapeutic Drug Monitoring:

Monitor trough levels before the next dose starting after the third loading dose 1. While the manufacturer doesn't routinely recommend monitoring for standard infections, it is specifically indicated when targeting troughs ≥20 mg/L 1.

Common Pitfalls:

  • Don't use standard 6 mg/kg loading doses - recent evidence shows conventional regimens fail to achieve therapeutic concentrations ≥20 mg/L within the first 72 hours, with probability of target attainment as low as 6.8-13.6% 2
  • Don't delay loading doses - the three-dose loading sequence over days 1-3 is essential for rapid attainment
  • Don't skip TDM - high clearance variability in HD patients (even with fixed dialysis schedules) necessitates concentration monitoring to maintain 20-40 mg/L range 2

Dose Adjustments Based on Levels

If trough monitoring reveals:

  • <20 mg/L: Increase maintenance dose to 12 mg/kg weekly or add supplemental doses
  • >40 mg/L: Reduce maintenance dose or extend dosing interval
  • 20-40 mg/L: Continue current regimen

The recent 2026 study demonstrated that even with optimized fixed-dose regimens (1600 mg loading, 800 mg maintenance), TDM improved probability of target attainment from ~60% to >70% in HD patients 2, underscoring the importance of concentration-guided adjustments in this population.

References

Guideline

national guidelines for the judicious use of glycopeptides in belgium.

Clinical Microbiology and Infection, 2000

Research

Model-based optimisation for teicoplanin dosing in patients undergoing maintenance haemodialysis.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.